



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Fidaxomicin](#) > [Printer-friendly PDF](#)

Fidaxomicin

Trade Name:

Dificid

Manufacturer/Distributor:

Optimer Pharmaceuticals Canada
www.optimerpharma.ca 1-855-343-4243

Classification:

Antibacterial agent

ATC Class:

J01FA - macrolide

Status:

active

Notice of Compliance (yyyy/mm/dd):

2012/06/07

Date Marketed in Canada (yyyy/mm/dd):

2012/06

Presentation:

Tablet: 200 mg. DIN: 02387174

Comments:

Optimer Pharmaceuticals is marketing fidaxomicin 200 mg tablets (Dificid) for the treatment of *C. difficile* infections. It is given orally for 10 days (200 mg bid) to treat infections that are proven or strongly suspected to be caused by *C. difficile*. Its activity is confined to the GI tract. It is indicated for those 18 years of age and older. Dosage adjustment is recommended for the elderly.

Source:

Letter from company

Keywords: fidaxomicin

clostridium infections

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

<Any>

Search Terms:

Apply

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|--|-----------------------------|---|---|
| <u>Abatacept</u> | Orencia | Co-stimulation modulator for rheumatoid arthritis | 2006/09 |
| <u>Abemaciclib</u> | Verzenio | Protein kinase inhibitor | 2019/07/03 |
| <u>Abiraterone</u> | Zytiga | Androgen biosynthesis inhibitor | 2011/08/08 |
| <u>Acamprosate</u> | Campral | Alcohol abstinence aid | 2007/03 |
| <u>Acidinium + formoterol</u> | Duaklir Genuair | Bronchodilator combination - LAMA plus LABA | 2015/07/09 |
| <u>Acidinium bromide</u> | Tudorza Genuair | Bronchodilator | 2013-09 |
| <u>Adapalene + benzoyl peroxide</u> | Tactuo | Acne therapy | 2011/04 |
| <u>Adefovir dipivoxil</u> | Hepsera | Antiviral agent | 2006/10 |
| <u>Afatinib</u> | Giotrif | Protein kinase inhibitor | 2014/05/28 |
| <u>Albiglutide</u> | Eperzan | Antihyperglycemic agent | 2016/02/19 |
| <u>Alendronate</u> | Fosamax | Bone resorption inhibitor | 2011/03 |
| <u>Alglucosidase alfa</u> | Myozyme | Enzyme replacement therapy | 2007/04 |
| <u>Aliskiren and hydrochlorothiazide</u> | Rasilez HCT | Renin inhibitor and diuretic | 2009/09 |
| <u>Alitretinoin</u> | Toctino | Immunomodulator, antiinflammatory agent | 2010/10/19 |
| <u>Alogliptin</u> | Nesina | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Alogliptin + metformin</u> | Kazano | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Alpelisib</u> | Piqray | Antineoplastic agent | 2020/03/11 |
| <u>Aluminum chloride hexahydrate</u> | Hydrosal gel | Antiperspirant | |
| <u>Aminophylline</u> | Phyllocontin | Bronchodilator | 2010 |

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|---|-----------------------------|---|---|
| <u>Apalutamide</u> | Erleada | Anti-androgen | 2018/07/27 |
| <u>Apixaban</u> | Eliquis | Anticoagulant | 2012/03 |
| <u>Apomorphine</u> | Movapo | Nonergot-derivative dopamine receptor agonist | 2018/04/xx |
| <u>Apomorphine</u> | Kynmobi | Nonergot-derivative dopamine receptor agonist | 2020/06/12 |
| <u>Apremilast</u> | Otezla | Immunosuppressant agent | 2014/12/08 |
| <u>Aripiprazole</u> | Abilify | Antipsychotic agent | 2009/07/03 |
| <u>ASA + Meprobamate + Codeine + Caffeine</u> | 282 MEP | Narcotic analgesic | |
| <u>Asenapine</u> | Saphris | Atypical antipsychotic | 2012/03/16 |
| <u>Asunaprevir</u> | Sunvepra | Antiviral agent | 2016/04/22 |
| <u>Avelumab</u> | Bavencio | Antineoplastic agent | 2017/12/18 |
| <u>Axicabtagene ciloleucel</u> | Yescarta | Antineoplastic agent | 2019/11/27 |
| <u>Axitinib</u> | Inlyta | Anti-tumor agent | 2012/09 |
| <u>Azacitidine</u> | Vidaza | Antineoplastic agent | 2009/12/07 |
| <u>Azelastine + fluticasone</u> | Dymista | Antihistamine and corticosteroid agent | 2015/10/22 |
| <u>Azilsartan</u> | Edarbi | Antihypertensive agent | 2013/03/27 |
| <u>Azilsartan + chlorthalidone</u> | Edarbyclor | Antihypertensive agent | 2013/03/27 |
| <u>Azithromycin dihydrate</u> | Zmax SR | Antibiotic | 2010/10/29 |

1 2 3 4 5 6 7 8 9 ? next ? last »

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2022-07-01 13:33): <http://www.dpic.org/druglisting/fidaxomicin>